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106Introduction: Previous studies have shown that focal low-energy extracorporeal shockwave therapy (Li-ESWT)
can have a positive effect in men with erectile dysfunction (ED). Linear Li-ESWT (LLi-ESWT) for ED has not
been previously assessed in a randomized trial.
Aim: To evaluate the treatment outcome of LLi-ESWT for ED.
Methods: Men with ED (n ¼ 126) and a score lower than 25 points on the International Index of Erectile
Function erectile function domain (IIEF-EF) were included. Subjects were allocated to receive LLi-ESWT once a
week for 5 weeks or sham treatment once a week for 5 weeks. After a 4-week break, the two groups received
active treatment once a week for 5 weeks. Subjects completed the IIEF, Erection Hardness Scale (EHS), Sexual
Quality of LifeeMen, and the Erectile Dysfunction Inventory of Treatment Satisfaction at baseline, after
9 weeks, and after 18 weeks.
Main Outcome Measures: The primary outcome measurement was an increase of at least ﬁve points on the
IIEF-EF score. The secondary outcome measurement was an increased EHS score to at least 3 in men with a
score no higher than 2 at baseline. Data were analyzed by linear and logistic regression.
Results: Mean IIEF-EF scores were 11.5 at baseline (95% CI ¼ 9.8e13.2), 13.0 after ﬁve sessions
(95% CI ¼ 11.0e15.0), and 12.6 after 10 sessions (95% CI ¼ 11.0e14.2) in the sham group and corre-
spondingly 10.9 (95% CI ¼ 9.1e12.7), 13.1 (95% CI ¼ 9.3e13.4), and 11.8 (95% CI ¼ 10.1e13.4) in the
ESWT group. Success rates based on IIEF-EF score were 38.3% in the sham group and 37.9% in the ESWT
group (odds ratio ¼ 0.95, 95% CI ¼ 0.45e2.02, P ¼ .902). Success rates based on EHS score were 6.7% in the
sham group and 3.5% in the ESWT group (odds ratio ¼ 0.44, 95% CI ¼ 0.08e2.61, P ¼ .369). A limitation of
this study is that device settings (number of shockwaves and penetration depth) were estimated based on an
existing trial on focused ESWT.
Conclusion: No clinically relevant effect of LLi-ESWT on ED was found.
J Sex Med 2017;14:106e112. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the Inter-
national Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Low-energy extracorporal shockwave therapy (Li-ESWT) is a
promising treatment modality in regenerative medicine.1,2
However, the mechanism of action of Li-ESWT is unknown.
The theory of mechano-transduction seems to be a plausible
explanation for its effect, in which the mechanical stimulation of
tissue changes the activity of cell membrane channels and affects
gene expression.3,4 Animal trials have indicated revascularization
after heart attack and stimulation of wound healing.5e7 Studies
on erectile dysfunction (ED) have shown that ESWT might
improve blood circulation in the penis,8,9 resulting inJ Sex Med 2017;14:106e112
Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age > 40 y Surgery or radiotherapy of pelvic region
Complaining of
ED > 6 mo
Treatment with anticoagulants
(except acetylsalicylic acid 75 mg)
In stable relationship
(>3 mo)
Treatment with antiandrogens
Anatomic penile deformation
or penile prosthesis
Total testosterone level < 8 nmol/dl
Serious heart or lung disease
Psychiatric or neurologic disorder
Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction 107spontaneous erection in contrast to existing on-demand treat-
ment.8 The effect of ESWT on ED has been evaluated in ﬁve
randomized trials using the focused delivery of shockwaves.8e12
Those results showed a positive effect on ED in a short-term
analysis. The use of linear ESWT has not been assessed in a
controlled trial.13 In medicine, shockwaves are generated by
applying one of three physical principles: electrohydraulic, elec-
tromagnetic, or piezoelectric. Most available therapy sources
deliver pulses focused on a spheroid area. Recently developed
linear devices are based on the same principles, but, thanks to a
modiﬁed conﬁguration of the transducer, they offer a larger
therapy zone that has an elliptical cylindrical form.Pregnant partner
IIEF-EF score  25
ED ¼ erectile dysfunction; IIEF-EF ¼ International Index for Erectile Function
erectile function domain.AIM
The objective of the present trial was to assess the efﬁcacy and
safety proﬁle of linear Li-EWST (LLi-ESWT) for ED.METHODS
The study was conducted as a randomized, double-blinded,
sham-controlled study in the Region of Southern Denmark.
Men were recruited after an article promoting the trial was
published in a local newspaper.14 Men applying to participate
in the study sent an email directly to the investigator or
requested their general practitioner for a referral to our clinic.
Patients complaining of ED during a consultation at our
outpatient clinic for other indications also were offered partic-
ipation in the trial. Included were men at least 40 years old in
stable relationships who had the complaint of ED for at least
6 months. During the ﬁrst visit, subjects were screened
according to the eligibility criteria and ﬁlled out the erectile
function domain of the Internation Index of Erectile Function
(IIEF-EF) questionnaire. We obtained the subjects’ medical
history and performed a physical examination. Subjects received
a written information form and were offered consideration
time. Serum glucose, lipid proﬁle, and total testosterone level
were assessed. When subjects met the inclusion criteria and
returned a signed consent form, they could enter the trial. All
subjects consented not to use other therapies for ED during the
study period. Participants previously treated for ED ceased
therapy 4 weeks before entering the study. Detailed inclusion
and exclusion criteria are listed in Table 1. A patient ﬂow
diagram is presented in Figure 1.
Participants gave written informed consent before the study.
The regional ethics committee (project ID-20120028), the
Danish Ministry of Health (DHMA 2013073909; CIV-13-07-
011546), and the regional data protection agency approved the
study. An independent good clinical practice unit at the
University of Southern Denmark monitored the research
process. The trial is registered at www.Clinicaltrials.gov
(NCT02063061).
The study was carried out in the Department of Urology at the
Hospital of Southern Jutland in Sønderborg, Denmark. This unitJ Sex Med 2017;14:106e112is responsible for the primary urologic care of more than 250,000
inhabitants in southern Denmark within a range of 100 km.
Screening of participants was performed from February 2014
through April 2014. Follow-up was carried out from June 2014
through August 2014.Randomization
A random list of numbers was generated (http://www.
randomization.com). When the participants met inclusion
criteria, they were allocated at a 1:1 ratio into two groups: one
group received LLi-ESWT and the other group initially received
sham treatment.Study Protocol
Each participant received two rounds of ﬁve weekly treatment
sessions with a 4-week interval. At baseline they completed the
IIEF, Erection Hardness Scale (EHS), and Sexual Quality of
LifeeMen (SQoL-M) questionnaires. When subjects met for the
second round at week 9, they completed the IIEF and EHS. The
two groups received active LLi-ESWT at the second round
without knowledge of the change. Subjects were informed that
they were assigned to an active or simulated treatment and that
all subjects would be offered active therapy if the results were
positive. To achieve good compliance, subjects received a short
text message on their mobile phone a day before each visit.
The follow-up visit was scheduled 4 weeks after the last ses-
sion, and participants completed the IIEF, EHS, SQoL-M, and
Erectile Dysfunction Inventory of Treatment Satisfaction
(EDITS) questionnaires (Figure 2). Subjects completed the
questionnaires using tablets in a separate room and were not
disturbed by other participants or investigators. A research nurse
was available to any subject who requested help. Subjects were
required to answer all questions to complete the survey.
Completed surveys were sent to a server that generated a table
with all responses (http://www.surveyexact.dk).
Figure 1. Extracorporal shockwave therapy for erectile dysfunction—Consolidated Standards of Reporting Trials (CONSORT) ﬂowchart.
108 Fojecki et alDuring each session, 600 shockwaves (energy ﬂux density ¼
0.09 mJ/mm2, frequency ¼ 5 Hz) were applied to the corpora
cavernosa using a piezoelectric linear therapy source (FBL10,
Richard-Wolf GmbH, Knitlingen, Germany). In total, 6,000
shockwaves were delivered during a period of 10 weeks in the
active group. The device is equipped with several gel pads, which
allow adjusting the depth of shockwave penetration. This study
used gel pad type 0, which covers an area 5 cm wide and 1 cm
deep. The dose was calculated based on an existing trial reportingFigure 2. Extracorporal shockwave therapy for erectile
dysfunction—study design. Figure 2 is available in color at www.
jsm.jsexmed.org.a positive outcome of ESWT using a focused transducer.8 Men
included in the study of Vardi et al8 received 1,500 pulses per
session (energy ﬂux density ¼ 0.09 mJ/mm2). Treatment was
administered twice a week for 3 weeks and repeated after a
3-week break. After adjusting for the fact that the linear trans-
ducer delivers shockwaves to a larger area of the penis, we
calculated the equivalent number of shockwaves that was deliv-
ered per square centimeter. With the subject standing up, 300
pulses were delivered to the penis shaft. The physician stretched
the penis by pulling the glans with the left hand and moving the
probe around the dorsal site of the penis at 3 to 9 o’clock with
the right hand. Subsequently, 150 pulses were delivered to each
crus in the lithotomy position. For coupling, a standard ultra-
sound gel was applied.Blinding
The subjects and the physician were blinded throughout the
trial. The manufacturer provided three identical-looking gel pads
to achieve double blinding. Sham treatment was delivered with a
gel pad that prevented the passage of energy. All gel pads were
tested at the manufacturer’s laboratory before the study and
properly marked. We used identical-looking gel pads in the
active and sham groups during the ﬁrst treatment round. During
the second round, we applied another active gel pad, which was
essential to maintain the concealed group allocation for the
investigator. The treatment device was set to the desired settings.J Sex Med 2017;14:106e112
Table 2. Subjects’ basic characteristics
ESWT (n ¼ 63) Sham (n ¼ 63)
Age (y), mean (SD) 65.4 (7.9) 63.3 (9.5)
BMI (kg/m2), mean (SD) 27.3 (3.8) 27.5 (3.4)
Total testosterone (nmol/dL),
mean (SD)
14.4 (4.7) 13.5 (4.1)
Smoking status, n (%) 7 (11.1) 15 (23.8)
Myocardial infarction, n (%) 8 (12.6) 7 (11.1)
Hypercholesterolemia, n (%) 44/26* (69.8) 49/28* (77.8)
Peripheral artery
disease, n (%)
8 (12.6) 3 (4.7)
Hypertension, n (%) 28 (44.4) 26 (41.2)
Diabetes, n (%) 6 (9.4) 9 (14.3)
Effect of previous treatment
with PDE-5i, n (%)
Responders 28 (44.4) 25 (39.7)
Non-responders 19 (30.2) 9 (14.3)
Never used 16 (25.4) 29 (46)
BMI ¼ body mass index; ESWT ¼ extracorporal shockwave therapy;
PDE-5i ¼ phosphodiesterase type 5 inhibitor.
*Diagnosed during inclusion assessment.
Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction 109The fact that ESWT treatment is painless further ensured that
the subjects and the physician were unaware of the group
allocation. Subjects in the two groups reported a slight pricking
or vibrating sensation in the penis while treatment was admin-
istrated. This phenomenon reported by the sham group was
probably due to the noise and vibrations of the probe because no
energy was transmitted through the sham pad. The investigator
wore a pair of cotton gloves under latex gloves to prevent energy
from passing through the tissue. Subjects were unblinded after
the ﬁnal follow-up visit.
The safety of the LLi-ESWT was monitored throughout the
study. At the beginning of each session, subjects were asked
about potential side effects that occurred between visits.
Furthermore, they reported any discomfort or sensations right
after each treatment. Subjects received a mobile phone number,
which was available 24 hours per day for 7 days per week,
allowing them to contact an investigator for any complication.
All adverse events were reported to the regional ethics committee
and the Danish Ministry of Health.
The primary investigator was responsible for screening the
subjects and performing the intervention and follow-up.MAIN OUTCOME MEASURES
The primary outcome measurement was the mean change of
IIEF-EF score. An increase of at least ﬁve points was considered a
signiﬁcant clinical effect.
Secondary outcome measurements consisted of changes in the
EHS score to at least 3, which indicates the penis is hard enough
for vaginal penetration. This was applied to men whose initial
score was no higher than 2 (n ¼ 83). Changes over time (0, 5,
and 10 treatments) of the IIEF-EF and EHS scores were assessed.
In addition, changes in subjects’ scores on sexual quality of life
(SQoL-M)15 and treatment satisfaction (EDITS)16 were
measured. The safety of the LLi-ESWT was monitored
throughout the trial.Statistics
The trial was powered for the primary end point assuming a
comparison of mean IIEF-EF values. The type I error was 5%
and the power was 80%. We expected a dropout rate of 10%.
Based on a comparison of independent means assuming a
common SD of 9.3, we calculated that 56 subjects in each group
were needed to show a difference of at least ﬁve points in the
primary end point. To account for dropouts, we aimed at
including 63 subjects in each group. We used linear regression
adjustment for baseline values to compare the means of the
primary outcome between treatment groups and logistic regres-
sion to assess the secondary end point of success related to the
improvement in IIEF-EF and EHS scores at any time. Change
over time was assessed and compared between groups using
mixed-effects linear regression, modeling the interaction with
time, and assuming random effects from subjects. All analysesJ Sex Med 2017;14:106e112were repeated explanatorily in the subgroup of responders to
phosphodiesterase type 5 inhibitor (PDE-5i). Outcomes are
presented with 95% CI and a P value less than .05 was
considered signiﬁcant. Analysis was performed using STATA 14
(STATA Corp, College Station, TX, USA).RESULTS
We screened 184 men from February through May 2014. Of
these, 126 participants were recruited for the study. Follow-up
was completed in September 2014. Baseline characteristics are
listed in Table 2.
Sixty of 63 men in the sham group and 58 of 63 men in the
active group were assessed in a modiﬁed intention-to-treat
analysis. Subjects who were found ineligible after randomiza-
tion (n ¼ 4 men who met all inclusion criteria but with a
baseline IIEF-EF score > 25) and those with missing primary
outcome data (n ¼ 4) were excluded (Figure 1).Primary Analysis
Mean IIEF-EF scores in the sham group were 11.5 at baseline
(95% CI ¼ 9.8e13.2) and 13 after ﬁve sham sessions (95%
CI ¼ 11e15). After an additional ﬁve active treatment sessions
in the second stage, the mean score was 12.6 (95% CI ¼
10.6e14.6). Mean scores in the active group were correspond-
ingly 10.9 (95% CI ¼ 9.1e12.7), 13.1 (95% CI ¼ 9.3e13.4),
and 11.8 (95% CI ¼ 9.3e13.4; Figure 3). Success rates based
on the IIEF-EF score were 38.3% in the sham group and
37.9% in the active group (odds ratio [OR] ¼ 0.95, 95%
CI ¼ 0.45e2.02, P ¼ .902). Success rates based on the EHS
score were 6.7% in the sham group and 3.5% in the active group
Figure 3. Change of International Index of Erectile Function
erectile function domain score. Figure 3 is available in color at www.
jsm.jsexmed.org.
110 Fojecki et al(OR ¼ 0.44, 95% CI ¼ 0.08e2.61, P ¼ .369). The predicted
change over time in the IIEF-EF score showed no statistically
signiﬁcant difference between treatment groups. Baseline values
for the SQoL-M score were 41.7 (95% CI ¼ 36.2e47.3) in the
sham group and 43.2 (95% CI ¼ 36.2e50.2) in the active
group, and the predicted values after 10 treatments were 43.3
(95% CI ¼ 36.7e49.9) and 45.4 (95% CI ¼ 37.6e53.2,
P ¼ .911), respectively. In the subgroup of responders to
PDE-5i, the mean IIEF-EF scores in the sham group were 12.7
at baseline (95% CI ¼ 9.7e15.7), 10.9 after ﬁve sessions
(95% CI ¼ 7.7e14.1), and 10.9 after 10 sessions (95%
CI ¼ 7.8e14). Correspondingly, scores in the active group were
12.2 (95% CI ¼ 9.4e15), 13.5 (95% CI ¼ 10.6e14.1), and 12
(95% CI ¼ 8.8e15.2). Similarly, no indications of signiﬁcant
results were seen for any of the other end points in the explor-
ative analyses. Furthermore, we noted similar low overall treat-
ment satisfaction EDITS scores of 50% in the sham group and
51% in the active group, which reﬂected the negative outcome.
We did not record any serious adverse events of LLi-ESWT.
Other than local irritation, no adverse effects were encountered.DISCUSSION
Treatment with focused Li-ESWT has been suggested to
improve erectile function in men with ED of vascular etiology.
Li-ESWT can stimulate the growth of new blood vessels,
potentially enabling penile tissue to regain the ability for spon-
taneous erection, and indeed previously published randomized
trials evaluating outcomes of ESWT on ED using focused
transducers have shown some effect on erectile function.8e12
Three trials found a signiﬁcant positive effect in the IIEF-EF
score,8,9,12 whereas two other trials found no signiﬁcant differ-
ence in the overall population for this outcome measure-
ment.10,11 However, a subgroup analysis of one of the latterstudies showed a positive effect in the group of men with severe
ED.10 Furthermore, in three trials including PDE-5i responders
only,8,11,12 a signiﬁcant positive effect was noted in the EHS
score, indicating that ESWT might be used to recover a natural
erection in this subgroup. A summary of cited studies is
presented in Table 3.
We applied standardized subjective outcome measurements
(IIEF-EF, EHS, and SQoL-M scores), because patients are
mainly interested in resolving their ED symptoms. Changes in
penile hemodynamics as assessed by Vardi et al8 and Kitrey et al9
showed a signiﬁcant increase in penile blood ﬂow after ESWT.
Applying hemodynamic measurements in the present series
might have added to the explanation of the data. None of the
previous published randomized trials included data on sexual
quality of life, which in our trial mirrored the outcome data. In
addition, treatment satisfaction (EDITS score) of ESWT on ED
has not been evaluated previously.
This study showed no improvement in erectile function in the
overall population. Furthermore, an analysis of PDE-5i
responders did not show any difference between the sham and
active groups. However, it should be noted that our trial was not
speciﬁcally powered for this purpose. This study included
PDE-5i responders and non-responders and men naive to the
treatment. Performing a study with more selective inclusion
criteria might have produced different results.
Overall the treatment was safe and well tolerated, and, as in all
existing trials, no serious adverse events were reported.8e12,17,18
Therefore, future trials on LLi-ESWT could safely explore the
effect of increasing the number of shockwaves and changing the
penetration depth. In general, anticoagulants should be
discontinued when applying ESWT.19 In our study, 10% of
patients received low-dose acetylsalicylic acid therapy (75 mg/d),
and no adverse effects were seen. Therefore, we consider the
administration of this medication safe during Li-EWST.
Strengths
The dropout rate was very low (3%) compared with previous
controlled trials (5% in Olsen et al,11 15% in Vardi et al8 and
Yee et al,10 and 40% in Srini et al12). Our design, which
promised all participants active treatment, could have helped
achieve the low dropout rate. In previously published controlled
studies, sequence generation was reported adequately in only
three of ﬁve trials,8,9,11 whereas the process of randomization was
unclear in the other trials.10,12 The randomization process of the
present study can be considered very robust in securely masking
allocation until the necessary number of subjects was achieved
and until data analysis was ﬁnalized. Furthermore, all phases of
the study, including data entry and management, were moni-
tored by an independent good clinical practice unit.Limitations
The results of our trial were obtained in routine clinical
settings and showed no positive effect of LLi-ESWT 4 weeksJ Sex Med 2017;14:106e112
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Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction 111after treatment. Comparison of baseline characteristics showed a
signiﬁcantly larger proportion of PDE-5i non-responders in the
active group. This difference could undermine the overall results.
However, the chosen study design should partly overcome
this limitation, because eventually the two groups received
LLi-ESWT, and we did not record improvement in the sham
group after the second stage of treatment.
Compared with previously published studies, the number of
pulses was smaller in the present trial. At the time we designed
our study, there was only one randomized controlled trial8
available and reports of non-randomized trials showing an
encouraging effect of Li-ESWT. Our dose was estimated based
on the trial of Vardi et al8 and an assumption that the linear
conﬁguration of shockwaves, covering a larger area of the penis
shaft and crura, would be more efﬁcient than the use of a focused
transducer. However, increasing the number of pulses and
changing the penetration depth might be more effective. This
possibility is supported by the results of an open-label study
performed by Bechara et al20 who applied a linear device (14,400
shockwaves during a period of 4 weeks). The energy ﬂux density
(0.09 mJ/mm2) applied in our trial was the same as in other
randomized controlled trials on ED.8e10,12 It is unknown
whether other treatment settings, such as the type of device
(electrohydraulic, electromagnetic, or piezoelectric), frequency,
or penetration depth, might inﬂuence the treatment outcome,
and further studies on these aspects are warranted. Furthermore,
we strongly recommend conducting a dose-ﬁnding study to
establish a treatment protocol before trials testing ESWT devices
for new indications.CONCLUSION
LLi-ESWT using 600 shockwaves per treatment session for
10 weeks (total ¼ 6,000 shockwaves) with an energy ﬂux density
of 0.09 mJ/mm2 and a frequency of 5 Hz did not improve
erectile function in men with ED. Future studies should evaluate
whether a larger number of pulses and changing the shockwave
penetration depth might increase efﬁcacy.Corresponding Author: Palle J.S. Osther, MD, PhD, Lillebaelt
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